Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: April Update

Performance overview

Value at beginning of month: $152,872.55

Value at end of month: $156,861.08

Month over month change: +2.61%

Total IRR: 21.74%

Related indices, monthly change

NASDAQ: +5.40%

IVV (iShares Core S&P 500): +3.83%

IBB (iShares NASDAQ Biotechnology Index): -3.94%

MXI (iShares Global Materials): +2.28%

VEGI (iShares MSCI Global Agriculture Producers): +1.79%

ICLN (iShares Clean Energy): +3.69%

Individual performances


Most companies showed a moderate increase in price, with Amyris posting the largest increase. They were coming back from a substantive decline earlier in the year, and is still negative on the year. Other than that, Kraig Biocraft made some great strides on new product announcements.

Changes made to index


You can view the index here.

Allocation as of April 26, 2019


Calvin Schmidt Synthetic Biology Index: May Update

Calvin Schmidt Synthetic Biology Index: March Update